Trial Type: Uterine Cancer

A Phase 3, Randomized Study to Compare MK28790 Versus Physicians Choice in Endometrial Cancer Who Have Received Prior Platinum based Chemotherapy and Immunotherapy.

A randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent of Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMatch Treatment Trial

A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors

A Phase 2 Multi-Center Open-Label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

A Phase 1b Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator’s Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

A phase III trial of the impact of sentinel lymph node mapping on patient reported lower extremity limb dysfuntion in endometrial cancer.